Understanding the CAR-T Treatment Process
Panelists discuss which patients are considered for CAR-T therapy in second-line treatment for relapsed/refractory multiple myeloma (R/R MM) (cilta-cel vs ide-cel), describe the specific criteria and institutional guidelines used to determine patient eligibility, and explore how non-medical factors like such as location and financial considerations impact patient selection, while also outlining the typical CAR-T referral process from community physician outreach to patient evaluation and selection.
EP: 1.Exploring CAR-T Therapy in Early Lines of Relapsed/Refractory Multiple Myeloma
EP: 2.Patient Selection and Referral Eligibility for CAR-T Therapy
EP: 3.Understanding the CAR-T Treatment Process
EP: 4.CAR-T Therapy: Approach to Bridging
EP: 5.Care Coordination and Transition Strategies for CAR-T Therapy
EP: 6.CAR-T Therapy in Early Lines of R/R MM: Clinical Scenario Discussion and Key Takeaways
EP: 7.Key Takeaways in CAR-T Therapy for Multiple Myeloma
Video content above is prompted by the following:
- Which patients do you think about consider for CAR-T in second-line treatment for R/R MM (cilta-cel vs ide-cel)?
- Can you describe the specific criteria/institutional guidelines used to determine patient eligibility for CAR-T referral?
- How do non-medical factors (location, money, etc) impact patient selection?
- Walk us through the typical CAR-T referral process at your institution, - from the initial community physician outreach to the patient evaluation and selection.
Considering NCCN Guidelines to Determine Maintenance Therapy Multiple Myeloma
February 15th 2025During the 66th American Society of Hematology Annual Meeting and Exposition, experts in multiple myeloma gathered to discuss the impact of maintenance therapy and minimal residual disease (MRD) in patients with newly diagnosed transplant-eligible or -ineligible multiple myeloma.
